Prothena Corporation plc (PRTA)
NASDAQ: PRTA · Real-Time Price · USD
11.07
-0.09 (-0.81%)
At close: Dec 5, 2025, 4:00 PM EST
11.00
-0.07 (-0.63%)
After-hours: Dec 5, 2025, 6:34 PM EST
Prothena Corporation Employees
Prothena Corporation had 163 employees as of December 31, 2024. The number of employees decreased by 10 or -5.78% compared to the previous year.
Employees
163
Change (1Y)
-10
Growth (1Y)
-5.78%
Revenue / Employee
$72,307
Profits / Employee
-$1,720,607
Market Cap
595.90M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PRTA News
- 16 days ago - Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025 - Business Wire
- 25 days ago - Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA - Business Wire
- 4 weeks ago - Prothena Reports Third Quarter 2025 Financial Results and Business Highlights - Business Wire
- 5 weeks ago - Prothena to Report Third Quarter 2025 Financial Results on November 6 - Business Wire
- 2 months ago - Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease - Business Wire
- 3 months ago - Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference - Business Wire
- 3 months ago - Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program - Business Wire
- 4 months ago - Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy - Business Wire